{"id":"W3029637120","doi":"10.1200/jco.19.03355","title":"ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":362,"is_retracted":false,"has_abstract":true,"ca_institutions":"Saint John Regional Hospital; University of New Brunswick","funders":"","keywords":"Bendamustine; Idelalisib; Medicine; Rituximab; Chronic lymphocytic leukemia; Refractory (planetary science); Internal medicine; Oncology; Leukemia; Lymphoma; Ibrutinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.01395224,0.0006166607,0.01077288,0.0005521682,0.00008113246,0.00002834777,0.001005794,0.00164734,0.002367613],"category_scores_gemma":[0.09644115,0.000399206,0.001945485,0.001110217,0.001546212,0.0002835259,0.0004001073,0.004031182,0.0001101105],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.09414819,"about_ca_system_score_gemma":0.3538572,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008635644,"about_ca_topic_score_gemma":0.0002941194,"domain_scores_codex":[0.9821843,0.00267039,0.01105176,0.000846517,0.002114411,0.001132663],"domain_scores_gemma":[0.9604957,0.03042021,0.005605872,0.0007982539,0.001028312,0.001651676],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9460105,0.003717092,0.000001847768,0.0004121599,0.001340236,0.0109132,0.0004863626,0.0006304926,0.0001837809,0.00005570946,0.008368178,0.02788048],"study_design_scores_gemma":[0.8185261,0.07638508,0.000006056435,0.0005387063,0.001533876,0.0007524462,0.0002826987,0.08024427,0.0001902563,0.00003618706,0.02119799,0.0003063109],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9823403,0.00212585,0.0003530938,0.004787802,0.004361278,0.00328856,0.00002840167,0.00006474442,0.002649967],"genre_scores_gemma":[0.9846014,0.00417642,0.002227983,0.001764313,0.006123945,0.00006143848,0.00002744701,0.0001081234,0.0009089108],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.259709,"threshold_uncertainty_score":0.999846,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2071622178590186,"score_gpt":0.5057558719860992,"score_spread":0.2985936541270806,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}